NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Apeloa Pharmaceutical Co.Ltd (SHE: 000739)
000739 Technical Analysis
2
As on 11th Mar 2025 000739 STOCK Price closed @ 15.54 and we RECOMMEND Buy for LONG-TERM with Stoploss of 14.94 & Strong Sell for SHORT-TERM with Stoploss of 17.33 we also expect STOCK to react on Following IMPORTANT LEVELS. |
000739STOCK Price
Open | 16.43 | Change | Price | % |
High | 16.60 | 1 Day | -1.69 | -9.81 |
Low | 15.51 | 1 Week | -1.38 | -8.16 |
Close | 15.54 | 1 Month | 0.09 | 0.58 |
Volume | 40897966 | 1 Year | -2.01 | -11.45 |
52 Week High 19.32 | 52 Week Low 11.04 |
SHE China Most Active Stocks
002195 | 6.97 | 9.94% |
002426 | 3.87 | 7.20% |
002131 | 4.31 | 1.17% |
300296 | 8.05 | 11.34% |
300451 | 7.65 | -4.73% |
300083 | 11.02 | 8.04% |
000592 | 3.18 | 10.03% |
000903 | 4.46 | 10.12% |
002122 | 5.41 | 4.44% |
000564 | 2.96 | 0.00% |
SHE China Top Gainers Stocks
SHE China Top Losers Stocks
000739 Daily Charts |
000739 Intraday Charts |
Whats New @ Bazaartrend |
000739 Free Analysis |
|
000739 Important Levels Intraday
RESISTANCE | 17.64 |
RESISTANCE | 16.97 |
RESISTANCE | 16.55 |
RESISTANCE | 16.13 |
SUPPORT | 14.95 |
SUPPORT | 14.53 |
SUPPORT | 14.11 |
SUPPORT | 13.44 |
000739 Forecast March 2025
4th UP Forecast | 23.9 |
3rd UP Forecast | 21.22 |
2nd UP Forecast | 19.56 |
1st UP Forecast | 17.91 |
1st DOWN Forecast | 13.17 |
2nd DOWN Forecast | 11.52 |
3rd DOWN Forecast | 9.86 |
4th DOWN Forecast | 7.18 |
000739 Weekly Forecast
4th UP Forecast | 17.74 |
3rd UP Forecast | 17.03 |
2nd UP Forecast | 16.60 |
1st UP Forecast | 16.16 |
1st DOWN Forecast | 14.92 |
2nd DOWN Forecast | 14.48 |
3rd DOWN Forecast | 14.05 |
4th DOWN Forecast | 13.34 |
000739 Forecast2025
4th UP Forecast | 32.96 |
3rd UP Forecast | 27.37 |
2nd UP Forecast | 23.92 |
1st UP Forecast | 20.47 |
1st DOWN Forecast | 10.61 |
2nd DOWN Forecast | 7.16 |
3rd DOWN Forecast | 3.71 |
4th DOWN Forecast | -1.88 |
Apeloa Pharmaceutical Co.Ltd ( SHE China Symbol : 000739 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
000739 Other Details
Segment | EQ | |
Market Capital | 39598272512.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
000739 Address
![]() |
000739 Latest News
000739 Business Profile
Apeloa Pharmaceutical Co.,Ltd researches and develops, produces, and sells pharmaceutical products in China and internationally. It provides products in the cardio-cerebrovascular, anti-infection, anti-viral, anti-tumor, and other treatment areas. The company offers preparations, raw material intermediates, and veterinary drugs primarily under the Tianliwei, Beshin, Yosemade, Jutai, and other brands. It also provides contract research and development, and production services for pharmaceutical companies. The company is headquartered in Dongyang, China. Address: No. 333, Jiangnan Road, Dongyang, China, 322118
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service